Magda Bahcall

1.8k total citations
13 papers, 589 citations indexed

About

Magda Bahcall is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Magda Bahcall has authored 13 papers receiving a total of 589 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 6 papers in Molecular Biology and 4 papers in Oncology. Recurrent topics in Magda Bahcall's work include Lung Cancer Treatments and Mutations (10 papers), Cancer Mechanisms and Therapy (3 papers) and HER2/EGFR in Cancer Research (3 papers). Magda Bahcall is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Cancer Mechanisms and Therapy (3 papers) and HER2/EGFR in Cancer Research (3 papers). Magda Bahcall collaborates with scholars based in United States, South Korea and United Kingdom. Magda Bahcall's co-authors include Pasi A. Jänne, Nathanael S. Gray, Taebo Sim, Yang Gao, Rani E. George, Lynette M. Sholl, Geoffrey R. Oxnard, Marzia Capelletti, Chelsea E. Powell and Eric S. Fischer and has published in prestigious journals such as Nature, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Magda Bahcall

13 papers receiving 581 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Magda Bahcall United States	8	388	324	278	66	54	13	589
K. T. Flaherty United States	15	461 1.2×	256 0.8×	356 1.3×	140 2.1×	57 1.1×	32	644
James A. Onori United States	4	254 0.7×	236 0.7×	224 0.8×	123 1.9×	46 0.9×	5	500
Mitchell D. Nambu United States	3	351 0.9×	271 0.8×	286 1.0×	76 1.2×	115 2.1×	3	648
Gregory Innocenti United States	3	360 0.9×	192 0.6×	209 0.8×	59 0.9×	58 1.1×	3	548
Weilong Yao China	12	378 1.0×	187 0.6×	166 0.6×	102 1.5×	57 1.1×	17	508
Shuta Ohara Japan	11	299 0.8×	405 1.3×	321 1.2×	108 1.6×	68 1.3×	37	627
Nele Van Der Steen Belgium	12	388 1.0×	202 0.6×	187 0.7×	147 2.2×	41 0.8×	21	560
B. Markman Australia	8	469 1.2×	152 0.5×	293 1.1×	69 1.0×	88 1.6×	20	688
L. Véronèse Switzerland	10	388 1.0×	280 0.9×	428 1.5×	71 1.1×	75 1.4×	17	664
S. Curley United States	8	287 0.7×	134 0.4×	274 1.0×	50 0.8×	70 1.3×	12	606

Countries citing papers authored by Magda Bahcall

Since Specialization

Citations

This map shows the geographic impact of Magda Bahcall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Magda Bahcall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Magda Bahcall more than expected).

Fields of papers citing papers by Magda Bahcall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Magda Bahcall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Magda Bahcall. The network helps show where Magda Bahcall may publish in the future.

Co-authorship network of co-authors of Magda Bahcall

This figure shows the co-authorship network connecting the top 25 collaborators of Magda Bahcall. A scholar is included among the top collaborators of Magda Bahcall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Magda Bahcall. Magda Bahcall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Kobayashi, Yoshihisa, Jiaqi Li, Kristin S. Price, et al.. (2022). Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers. Nature. 603(7900). 335–342. 31 indexed citations

Pecci, Federica, Biagio Ricciuti, Joao V. Alessi, et al.. (2022). Activating MET kinase domain mutations define a novel molecular subtype of non–small cell lung cancer that is clinically targetable with the MET inhibitor elzovantinib (TPX-0022).. Journal of Clinical Oncology. 40(16_suppl). 9124–9124. 1 indexed citations

Recondo, Gonzalo, Magda Bahcall, Lynette M. Sholl, et al.. (2019). MA09.11 Mechanisms of Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14 Mutant Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S285–S285. 4 indexed citations

Awad, Mark M., Magda Bahcall, Lynette M. Sholl, et al.. (2018). Mechanisms of acquired resistance to MET tyrosine kinase inhibitors (TKIs) in MET exon 14 (METex14) mutant non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 36(15_suppl). 9069–9069. 6 indexed citations

Powell, Chelsea E., Yang Gao, Li Tan, et al.. (2018). Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK). Journal of Medicinal Chemistry. 61(9). 4249–4255. 156 indexed citations

Kosaka, Takayuki, Junko Tanizaki, Raymond M. Paranal, et al.. (2017). Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors. Cancer Research. 77(10). 2712–2721. 100 indexed citations

Jang, Jaebong, Ciric To, Magda Bahcall, et al.. (2017). Discovery of a potent dual ALK and EGFR T790M inhibitor. European Journal of Medicinal Chemistry. 136. 497–510. 42 indexed citations

Ivanova, Elena V., Magda Bahcall, Ting Chen, et al.. (2017). MA 07.12 Short-Term Culture of Patient Derived Tumor Organoids Identify Neratinib/Trastuzumab as an Effective Combination in HER2 Mutant Lung Cancer. Journal of Thoracic Oncology. 12(11). S1829–S1830. 3 indexed citations

Bahcall, Magda, Yanan Kuang, Cloud P. Paweletz, & Pasi A. Jänne. (2017). Abstract 4100: Mechanisms of resistance to type I and type II MET inhibitors in non-small cell lung cancer. Cancer Research. 77(13_Supplement). 4100–4100. 2 indexed citations

10.

Bahcall, Magda, Taebo Sim, Cloud P. Paweletz, et al.. (2016). Acquired MET D1228V Mutation and Resistance to MET Inhibition in Lung Cancer. Cancer Discovery. 6(12). 1334–1341. 114 indexed citations

11.

Chong, Curtis R., Magda Bahcall, Marzia Capelletti, et al.. (2016). Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer. Clinical Cancer Research. 23(1). 204–213. 67 indexed citations

12.

Tanizaki, Junko, Dalia Ercan, Marzia Capelletti, et al.. (2015). Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2. Cancer Research. 75(15). 3139–3146. 30 indexed citations

13.

Hatcher, John M., Magda Bahcall, Hwan Geun Choi, et al.. (2015). Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. Journal of Medicinal Chemistry. 58(23). 9296–9308. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact